Related Experiment Videos
Multimodality treatment in advanced primary liver cancer
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1995
Summary
Surgery is the primary treatment for primary liver cancer (PLC). Long-term results show improved survival with resection, especially for smaller tumors, and potential benefits from multimodal approaches for advanced cases.
Area of Science:
- Hepatology
- Surgical Oncology
- Gastroenterology
Background:
- Primary liver cancer (PLC) is a significant health concern, often coexisting with liver cirrhosis.
- Understanding long-term outcomes of various treatment modalities is crucial for patient management.
Purpose of the Study:
- To report long-term results of multimodality treatment for primary liver cancer (PLC) over three decades.
- To evaluate the efficacy of different surgical and therapeutic interventions for PLC.
Main Methods:
- Retrospective analysis of 1639 patients with pathologically proven PLC treated over 30 years.
- Comparison of survival rates across different treatment groups: resection, palliative surgery (hepatic artery ligation/infusion), second-look resection, and cryosurgery.
Main Results:
- The overall 5-year survival after PLC resection was 45.5%, significantly higher (62.7%) for tumors <= 5 cm.
- Palliative surgery (HAL + HAI) showed a 5-year survival of 18.1%, better than palliative resection (12.5%).
- Second-look resection yielded a 5-year survival of 68.4%, and cryosurgery showed 22.0% 5-year survival.
Conclusions:
- Surgery remains the preferred treatment modality for primary liver cancer (PLC).
- Multimodality treatment, second-look resection, and novel surgical techniques offer promise for advanced or unresectable PLC.
- Palliative surgery outcomes suggest HAL + HAI may be more effective than palliative resection.